The Serum Institute of India (SII) was selected not only by Oxford University for the manufacturing of their vaccine doses, but also by Novavax, recently.
Novavax and SII recently entered their deal where SII is to manufacture their vaccine doses for India and other low- and middle-income countries.
According to the latest reports, SII is to manufacture 100 Crore doses (1 billion) of Novavax’s vaccine. SII has also expressed confidence over this vaccine, saying that Novavax has a good record when it comes to developing vaccines, especially keeping in mind the vaccines that it developed for malaria.
Earlier this month, Novavax had reported that its vaccine candidate was generally well-tolerated and elicited robust antibody responses numerically superior to that seen in human convalescent sera in Phase I and Phase II trials.